ArticleAntimicrobial agents and chemotherapy2010
Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.British journal of clinical pharmacology · 2018Trial
- Repositioning Antibiotics Against Plasmodium falciparum RAD5 and WD11 as Novel Antimalarial Targets.Tropical medicine & international health : TM & IH · 2026Article
- Metal-antibiotic interactions: potentiometric and spectroscopic investigation of cloxacillin and dicloxacillin complexes in aqueous solution.Scientific reports · 2026Article
- Expression patterns of core metabolic genes and elevated intracellular ROS confer drug tolerance inMicrobiology spectrum · 2026Article
- DEAD-box ATPase-marked condensates coordinate compartmentalized translation and antibiotic persistence.Science advances · 2026Article
- Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in anAntimicrobial agents and chemotherapy · 2021Article
- Development of Antimicrobial Phototreatment Tolerance: Why the Methodology Matters.International journal of molecular sciences · 2021Review
- Ginger (Zingiber officinale) phytochemicals-gingerenone-A and shogaol inhibit SaHPPK: molecular docking, molecular dynamics simulations and in vitro approaches.Annals of clinical microbiology and antimicrobials · 2018Article
- Increased intracellular activity of MP1102 and NZ2114 against Staphylococcus aureus in vitro and in vivo.Scientific reports · 2018Article
- Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.Drug design, development and therapy · 2017Article
- In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.Antimicrobial agents and chemotherapy · 2016Article
- Distinguishing between resistance, tolerance and persistence to antibiotic treatment.Nature reviews. Microbiology · 2016Review
- Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages.Antimicrobial agents and chemotherapy · 2015Article
- The immune response and antibacterial therapy.Medical microbiology and immunology · 2015Review
- Antibiotic selection of Escherichia coli sequence type 131 in a mouse intestinal colonization model.Antimicrobial agents and chemotherapy · 2014Article
- Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?Nature reviews. Microbiology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic treatment of Staphylococcus aureus infections is often problematic due to the slow response and recurrences. The intracellular persistence of the staphylococci offers a plausible explanation for the treatment difficulties because of the impaired intracellular efficacies of the antibiotics. The intra- and extracellular time- and concentration-kill relationships were examined in vitro with THP-1 cells and in vivo by use of a mouse peritonitis model. The in vivo model was further used to estimate the most predictive pharmacokinetic/pharmacodynamic (PK/PD) indices (the ratio of the maximum concentration of drug in plasma/MIC, the ratio of the area under the concentration-time curve/MIC, or the cumulative percentage of a 24-h period that the free [f] drug concentration exceeded the MIC under steady-state pharmacokinetic conditions [fT(MIC)]) for dicloxacillin (DCX) intra- and extracellularly. In general, DCX was found to have similar intracellular activities, regardless of the model used. Both models showed (i) the relative maximal efficacy (1-log-unit reduction in the numbers of CFU) of DCX intracellularly and (ii) the equal relative potency of DCX intra- and extracellularly, with the MIC being a good indicator of the overall response in both situations. Discordant results, based on data obtained different times after dosing, were obtained from the two models when the extracellular activity of DCX was measured, in which the in vitro model showed a considerable reduction in the number of CFU from that in the original inoculum (3-log-unit decrease in the number of CFU after 24 h), whereas the extracellular CFU reduction achieved in vivo after 4 h did not exceed 1 log unit. Multiple dosing of DCX in vivo revealed increased extra- and intracellular efficacies (2.5 log and 2 log units of reduction in the numbers of CFU after 24 h, respectively), confirming that DCX is a highly active antistaphylococcal antibiotic. PK/PD analysis revealed that fT(MIC) is the index that is the most predictive of the outcome of infection both intra- and extracellularly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.